Successful Conclusion to the Global Strategic Conference of Beroni Group
Group Picture

Successful Conclusion to the Global Strategic Conference of Beroni Group

The Global Strategic Conference of Beroni Group was held successfully in Tokyo, Japan from 30th September 2018 to 4th October 2018, which were attended by Mr. Jacky Zhang, Executive Chairman of Beroni Group, other directors and senior management from Australia, Japan and China.

H.E.Yukio Hatoyama, Japan's former Prime Minister
H. E.Yukio Hatoyama, Japan’s former Prime Minister
warmly welcomed the representatives of Beroni Group to Japan

 

A key objective of the conference was an evaluation of the current organization structure and business development plans in the countries where the Group has a business presence. The strategic conference also involved evaluating the current business situation against a number of product and market development strategies with a view to developing a robust and sustainable five-year business plan for the Group.

Mr. Jacky Zhang
Mr. Jacky Zhang, Executive Chairman of Beroni Group making his opening speech
Mr. Peter Wong
Mr. Peter Wong, Executive Director and CFO of Beroni Group talking about financial strategy
Mrs. Xiaoli Duan
Mrs. Xiaoli Duan, CFO of Beroni China making a speech on fending off risks

 

Based on this strategic plan, Beroni aspires to become a world’s leading biotechnology company contributing significantly to improving the human health. Its new strategy will focus on developing 5 pillars of the business, including strengthening the board and management team, diversifying its products and expanding into new markets, becoming a billion dollar value company, collaborating with strategic partners to develop new technologies and expand existing businesses and establishing a strong brand name and reputation.

speeches on business developments in Japan
Mrs. Kinuko Fujiwara, President of Beroni Japan (a subsidiary of Beroni Group) and Mr. Yoshiaki Hosaka, Vice-president of Beroni Japan delivering speeches on business developments in Japan

In addition, the outcome of this review led to a realignment of its business model which are now re-organized into four core businesses:
Firstly, to carry out scientific research and innovation in the field of precision medicine, especially in developing and innovating the cell therapy business. Beroni Group plans to  expand the cell therapy business through Beroni Japan and Youtokukai’s Ginza Medical Clinic.

Pro. Katsuo Noguchi
Pro. Katsuo Noguchi, Chief Scientist (Japan) of Beroni Group giving a talk on DC vaccine

Secondly, to develop new anti-cancer drugs. As part of its collaboration with the University of NSW, Beroni is investing in the development of a new anti-cancer drug PENAO which will commence Phase Ⅱ clinical trial next year. Beroni will be on the look-out for opportunities to develop new anti-cancer drugs with other medical research institutions.

Professor Hogg
Professor Hogg, Principal of PENAO project from UNSW, Sydney delivering a speech

 

Thirdly, to develop diagnostic tools for detecting infectious diseases. Through its research sponsorship with Columbia University, Beroni is working to secure the distribution rights to six markets namely Australia, Saudi Arabia, USA, China, Japan and India for the distribution of the CII-ArboViroPlex rRT-PCR assay, a diagnostic kit used to detect viruses such as Zika, Dengue, Chikungunya and West Nile.

Mr. Zhenghu Jia
Mr. Zhenghu Jia, Representative of Beroni USA making a speech

 

Fourthly, to establish a strong e-commerce platform for sales of pharmaceutical and healthcare products.  Medicine Plus, an affiliate of Beroni Group, provides a wide range of medical drugs, health foods, supplements, cosmetic products and household goods in the Japanese market. Its products are sold to over 2,000 distributors and 7,500 sales outlets, such as chemists, clinics, dentists, supermarkets and other retail outlets. Its e-commerce business is the fastest growing of its sales channels, with an existing membership base of almost 850,000 consumers. In addition, MP also has a significant presence on the popular e-commerce sites in Japan such as Rakuten, Yahoo and Amazon.  Beroni Group will help MP promote its third-party marketing business using its outstanding e-commerce’s operational experience and efficient warehouse logistics & delivery management system. At the same time, Beroni Group will expand the sales of its pharmaceutical and healthcare products through its established e-commerce platform in Japan and China to other countries in Asia.

Professor Zhihe Hu, China CTO of Beroni Group making a speech
Professor Zhihe Hu, China CTO of Beroni Group making a speech
Mr. Dejun Kim, CEO designate of Medicine-Plus making a speech on developing e-commerce business
Mr. Dejun Kim, CEO designate of Medicine-Plus making a speech on developing e-commerce business
Mr. Hai Huang, Executive Director of Beroni Group talking about core businesses
Mr. Hai Huang, Executive Director of Beroni Group talking about core businesses

Beroni’s Executive Chairman Mr. Jacky Zhang said the new strategy, by leveraging its business presence in Japan, USA, Australia and China, would lead to an acceleration of growth and internationalisation of the business of Beroni Group. The Chinese domestic medical biotechnology sector has enjoyed dynamic growth in the last few years due to a combination of policy support, industry regulation and sizable capital market.  As part of its Made in China 2025 strategic plan, the Chinese government has targeted the rapid development of high-tech fields, including the pharmaceutical industry, from 2015 to 2025. Beroni will take advantage of its new technologies and international connections to fast track the development of its core businesses in the massive Chinese market, Zhang was quoted as saying in his speech.

Mr. Zhenghu Jia, Vice-President of Beroni R&D Center for Precision Medicine asking questions
Mr. Zhenghu Jia, Vice-President of Beroni R&D Center for Precision Medicine asking questions
Mr. Jacky Zhang, Executive Chairman of Beroni Group making his concluding remarks
Mr. Jacky Zhang, Executive Chairman of Beroni Group making his concluding remarks

The conference has effectively evaluated the issues currently faced by the Group and discussed the various solutions. Upholding the principle of seeking truth from facts, the directors, chief scientists, and senior management were able to speak out freely and honestly, and worked together to devise a future plan for Beroni Group. It has turned out to be a successful and rewarding conference.

Group Picture
Group Picture
Close Menu